Physicians of MedicinePhysician-led obesity medicine care
Request an Appointment
Injectable GLP-1 Medications

A New Era in Medicine

Injectable GLP-1 and GIP/GLP-1 medications continue to push new frontiers in the treatment of diabetes, obesity, and related metabolic disease.

For many patients, these medications may help improve blood sugar, support clinically remarkable weight loss, and assist with long-term weight control.

Patients now have three pathways to explore GLP-1 and related medical weight control treatment options: diabetes treatment, unhealthy weight treatment, and self-pay or direct pay access.

Some patients want to use insurance when available. Others prefer the fastest route, with fewer insurance delays or prior authorization hurdles. At Physicians of Medicine, treatment decisions remain physician-led and individualized.

Physician-led decision

The medication class may sound familiar, but the right medication, diagnosis, and pathway depend on medical history, contraindications, goals, and access. An obesity-trained physician will best lead you through the GLP-1 options and other medical weight control medications.

Ozempic pen
Wegovy pen
Mounjaro single-injection pen
Zepbound single-injection pen

Same class.
Three pathways.
Different coverage logic.

GLP-1 Meds CLASS
Pathway 3: Self-Pay DIRECT ACCESS
Insurance Authorization POSSIBLE DELAYS
Pathway 1: Diabetes GLYCEMIC CONTROL Pathway 2: Unhealthy Weight WEIGHT MANAGEMENT
Pathway 1: Diabetes Pathway 2: Unhealthy Weight Pathway 3: Self-Pay
Ozempic pen image
Mounjaro single-injection pen image
Mounjaro KwikPen image
Pathway 1

Diabetes

  • Anchored by a type 2 diabetes diagnosis.
  • Common discussion: Ozempic, Mounjaro, and other diabetes-focused injectables.
  • Insurance often looks at A1c, prior diabetes therapy, and medical necessity.
Wegovy pen image
Zepbound single-injection pen image
Zepbound KwikPen image
Zepbound vial image
Pathway 2

Unhealthy Weight

  • Anchored by obesity or overweight with risk conditions.
  • Common discussion: Wegovy and Zepbound.
  • Insurance may look at BMI criteria, weight-related conditions, and prior authorization requirements.
Ozempic pen image
Mounjaro single-injection pen image
Mounjaro KwikPen image
Wegovy pen image
Zepbound single-injection pen image
Zepbound KwikPen image
Zepbound vial image
Pathway 3

Pathway 3 Self-pay

  • Self-pay or direct pay may be the fastest path for patients who want to move forward without waiting on insurance approval.
  • This option can reduce delays from coverage restrictions, prior authorizations, or plan exclusions.
Explore More Resources

Compare GLP-1 Pill Prices

Check out the latest monthly pricing and dosing tables for Wegovy® Pill and Foundayo™ on our public dashboard.

View GLP-1 Pill Prices →

Injectable Options

Learn more about subcutaneous injectables including Ozempic®, Wegovy®, Mounjaro®, and Zepbound®.

Explore Injections →

GLP-1 Pill Options

Compare clinical outcomes, dosing frequencies, and requirements for GLP-1 pill weight-loss options.

Which weight loss pill is better? →

Take Action — Start Your Journey Today

Determine your eligibility with a comprehensive physician-led evaluation. Partner with board-certified physicians to receive personalized, evidence-based obesity medicine care.

Join the Waitlist & Request an Appointment →
Public education only. Injectable GLP-1 and GIP/GLP-1 medications require prescription evaluation and ongoing monitoring. Not everyone is a candidate. Medication choice, diagnosis, eligibility, safety, and access vary by patient and insurance plan. This page uses Physicians of Medicine reference imagery for Ozempic, Wegovy, and Zepbound, and a styled illustration for Mounjaro. Wegovy and Zepbound indication notes were written to reflect current official prescribing-information themes, including cardiovascular-risk reduction for Wegovy and obstructive sleep apnea for Zepbound, while liver disease questions such as MASH still require individualized physician review.